Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1006875-83-7

tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate is a complex organic compound that serves as a key intermediate in the synthesis of various pharmaceutical agents. It is characterized by its unique structure, which includes a tert-butyl group, a 1H-pyrazol-1-yl moiety, and a 1,3,2-dioxaborolan-2-yl functional group. tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate plays a crucial role in the development of novel therapeutics, particularly in the area of kinase inhibitor research.

1006875-83-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

  • tert-butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate

    Cas No: 1006875-83-7

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier

  • TERT-BUTYL 2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1H-PYRAZOL-1-YL)ACETATE

    Cas No: 1006875-83-7

  • No Data

  • No Data

  • No Data

  • coolpharm Ltd
  • Contact Supplier
  • 1006875-83-7 Structure

  • Basic information

    1. Product Name: tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate
    2. Synonyms: tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate;tert-butyl [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]acetate
    3. CAS NO:1006875-83-7
    4. Molecular Formula: C15H25BN2O4
    5. Molecular Weight: 308.181
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1006875-83-7.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 407.4±25.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.08±0.1 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
    8. Solubility: N/A
    9. PKA: 1.45±0.10(Predicted)
    10. CAS DataBase Reference: tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate(CAS DataBase Reference)
    11. NIST Chemistry Reference: tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate(1006875-83-7)
    12. EPA Substance Registry System: tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate(1006875-83-7)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1006875-83-7(Hazardous Substances Data)

1006875-83-7 Usage

Uses

Used in Pharmaceutical Industry:
tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate is used as a reactant in the preparation of imidazotriazines and imidazopyrimidines. These compounds are of significant interest as they possess the potential to act as kinase inhibitors. Kinase inhibitors are a class of drugs that can block the activity of enzymes known as kinases, which are often implicated in the development and progression of various diseases, including cancer and inflammatory disorders. By inhibiting kinase activity, these compounds can help regulate cellular processes and potentially lead to therapeutic benefits for patients.
In the synthesis of imidazotriazines and imidazopyrimidines, tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate serves as a versatile building block, enabling the creation of diverse chemical entities with potential biological activity. Its unique structure allows for the formation of stable intermediates and final products that can be further optimized for improved potency, selectivity, and pharmacokinetic properties.
Overall, the use of tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate in the pharmaceutical industry highlights its importance in the development of innovative therapeutic agents targeting kinase-related diseases. Its role in the synthesis of imidazotriazines and imidazopyrimidines underscores its potential as a valuable tool in the ongoing pursuit of new and effective treatments for a wide range of health conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 1006875-83-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,6,8,7 and 5 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1006875-83:
(9*1)+(8*0)+(7*0)+(6*6)+(5*8)+(4*7)+(3*5)+(2*8)+(1*3)=147
147 % 10 = 7
So 1006875-83-7 is a valid CAS Registry Number.

1006875-83-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]acetate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1006875-83-7 SDS

1006875-83-7Relevant articles and documents

PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF

-

Page/Page column 476, (2021/06/26)

Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer 5 or a metabolic disease.

CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE

-

Page/Page column 112-113, (2020/09/12)

Bivalent compounds composition comprises one or more of the bivalent compounds. The bivalent compound comprises a cyclic-AMP response element binding protein (CBP) and/or adenoviral E1A binding protein of 300kDa (P300) ligand (CBP/P300 ligand) conjugated

AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF

-

Paragraph 0507-0509, (2020/01/31)

The present invention aims to provide a compound that: has an excellent cytotoxic action on cancer cells, excellent induction of BET protein degradation in cancer cells, and an excellent binding-inhibiting action on BET protein and acetylated histone; and is effective as an anti-cancer agent, a BET protein degradation-inducing agent, or a BET protein inhibiting agent. A compound indicated in general formula (I) or a pharmacologically acceptable salt thereof. {In the formula, each symbol is as outlined in the Description.}

PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS

-

Page/Page column 170, (2019/11/12)

The present invention provides pyridazine derivatives of formula (I), which are therapeutically useful as SMARCA2/4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2/4 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the pyridazine derivatives of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof.

Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same

-

Paragraph 1111-1114, (2018/05/17)

The present invention relates to a novel autotaxin inhibitor compound for preventing and treating disease or symptoms due to an increase in concentration of lysophosphatidic acid or activation of autotaxin. The present invention further relates to a pharmaceutical composition containing the same. The novel compound of the present invention is an autotaxin inhibitor which inhibits production of lysophosphatidic acid, and thus is useful for treating or preventing cardiovascular disease, cancer, metabolic disease, kidney disease, liver disease, inflammatory diseases, nervous disease, respiratory disease, desmoid disease, eye disease, cholestatic symptoms, other types of chronic pruritus or acute, or chronic rejection of transplanted organs.COPYRIGHT KIPO 2017

SUBSTITUTED PHTHALAZINES

-

Page/Page column 49; 50, (2016/09/22)

Provided are compounds of formula (I), Wherein R 1, R 2, R 3, R 4, R 5 and R 6 are as defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents

USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS

-

Paragraph 0424, (2014/09/16)

The present application provides methods of treating PI3Kδ related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.

HYDRATE AND CRYSTAL OF FLUORENE COMPOUNDS

-

Paragraph 0286; 0287; 0288, (2014/10/16)

A compound represented by the formula (J): or a crystal thereof, or a compound represented by the formula (Q): or a crystal thereof.

HETEROCYCLYLAMINES AS PI3K INHIBITORS

-

Paragraph 1146, (2013/03/26)

The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

Fluorene Compound and Pharmaceutical Use Thereof

-

Page/Page column 57-58, (2010/10/03)

The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ische

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1006875-83-7